Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
28 hedge funds and large institutions have $456K invested in Argos Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 29 → 28 (-1)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
84% less capital invested
Capital invested by funds: $2.89M → $456K (-$2.44M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.6K |
| 2 |
VF
Virtu Financial
New York
|
+$10.9K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$6.71K |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$4.86K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$32K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$17.1K |
| 3 |
PI
Pharmstandard International
Luxembourg
|
-$16.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$15.7K |
| 5 |
Bank of New York Mellon
New York
|
-$8.44K |
ARGS Hedge Fund Activity: Q4 2017 in Review
28 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q4 2017, worth a combined $456K — down 84% from $2.89M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ARGS and 5 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $32.6K. The largest seller was Millennium Management, exiting entirely with an estimated $32K sold.
- 28 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q4 2017, down from 29 in Q3 2017.
- Funds reported $456K of Argos Therapeutics, Inc. stock for Q4 2017, down 84% quarter-over-quarter.
- 5 funds opened new Argos Therapeutics, Inc. positions in Q4 2017 and 6 closed out, a net change of -1 holder.
- The largest Argos Therapeutics, Inc. buyer in Q4 2017 was Vanguard Group, an estimated $32.6K added.
- The largest Argos Therapeutics, Inc. seller in Q4 2017 was Millennium Management, an estimated $32K sold.
Based on aggregated 13F filings for Q4 2017.